Outcomes of patients treated with CAR T-cell therapy who were admitted to intensive care
Prof. Élie Azoulay
The multinational CARTTAS study investigated outcomes of patients treated with CAR T-cell therapy who were admitted to intensive care, mostly due to CRS and ICANS. Admission to intensive care was needed for 27% of patients, within median 4.5 days of CAR T-cell infusion. The 90-day mortality rate was 22.4%.
